Moleculin Biotech, Inc. (MBRX)
0.77
+0.02
(+2.65%)
USD |
NASDAQ |
Sep 09, 15:06
Moleculin Biotech Total Liabilities (Quarterly) : 9.50M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 9.50M |
| March 31, 2026 | 8.18M |
| December 31, 2025 | 7.12M |
| September 30, 2025 | 47.27M |
| June 30, 2025 | 28.76M |
| March 31, 2025 | 20.97M |
| December 31, 2024 | 5.717M |
| September 30, 2024 | 5.717M |
| June 30, 2024 | 7.87M |
| March 31, 2024 | 9.258M |
| December 31, 2023 | 12.14M |
| September 30, 2023 | 4.385M |
| June 30, 2023 | 6.847M |
| March 31, 2023 | 5.378M |
| December 31, 2022 | 5.231M |
| September 30, 2022 | 6.955M |
| June 30, 2022 | 6.896M |
| March 31, 2022 | 6.136M |
| December 31, 2021 | 5.097M |
| September 30, 2021 | 7.443M |
| June 30, 2021 | 8.834M |
| March 31, 2021 | 11.27M |
| Date | Value |
|---|---|
| December 31, 2020 | 11.27M |
| September 30, 2020 | 12.68M |
| June 30, 2020 | 15.75M |
| March 31, 2020 | 10.18M |
| December 31, 2019 | 9.664M |
| September 30, 2019 | 11.42M |
| June 30, 2019 | 9.762M |
| March 31, 2019 | 6.616M |
| December 31, 2018 | 5.313M |
| September 30, 2018 | 5.931M |
| June 30, 2018 | 7.318M |
| March 31, 2018 | 4.359M |
| December 31, 2017 | 2.365M |
| September 30, 2017 | 1.982M |
| June 30, 2017 | 1.98M |
| March 31, 2017 | 4.175M |
| December 31, 2016 | 1.433M |
| September 30, 2016 | 1.330M |
| June 30, 2016 | 1.253M |
| March 31, 2016 | 0.978M |
| December 31, 2015 | 0.7728M |
| September 30, 2015 | 0.3326M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 436.29M |
| Alnylam Pharmaceuticals, Inc. | 4.205B |
| Anika Therapeutics, Inc. | 46.19M |
| Savara, Inc. | 48.48M |
| Vericel Corp. | 132.82M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 21.09M |
| Shareholders Equity (Quarterly) | 11.59M |
| Debt to Equity Ratio | 0.0252 |
| Current Ratio | 0.9366 |
| Net Debt Paydown Yield | 0.16% |